Cadrenal Therapeutics Strengthens Anticoagulation Pipeline by Acquiring eXIthera's Factor XIa Inhibitor Portfolio

Acquisition Overview: Cadrenal Therapeutics has acquired assets from eXIthera Pharmaceuticals, including novel intravenous and oral Factor XIa inhibitors, significantly enhancing its pipeline in the $38 billion global anticoagulation market.

Product Details: The lead asset, frunexian, is a Phase 2-ready IV Factor XIa inhibitor for acute care, while EP-7327 is an oral candidate for chronic indications, both aimed at addressing critical gaps in current anticoagulation therapies.

Strategic Positioning: Cadrenal aims to become a leader in anticoagulation by developing unique therapeutics, including tecarfarin, a novel vitamin K antagonist, to better serve patients with cardiovascular thrombotic risks.

Financial Terms: The acquisition includes milestone payments of up to $15 million to eXIthera, along with royalties on future global sales, allowing Cadrenal to focus on advancing its clinical development efforts.